Reno, Nevada (September 4, 2024) – Saint Mary’s Regional Medical Center, a member of Prime Healthcare, is thrilled to improve access to industry-leading treatment interventions through the introduction the FARAPULSE™ Pulsed Field Ablation (PFA) system. FARAPULSE, developed by Boston Scientific, is used for the treatment of atrial fibrillation (AF), the most commonly diagnosed arrhythmia in clinical practice.
The FARAPULSE System is a unique, new alternative to standard-of-care thermal ablation. As FARAPULSE is a non-thermal approach, it is proven to be an effective treatment option for patients while minimizing risks associated with thermal ablation. During a traditional ablation procedure, a catheter is guided to the interior of the heart and generates extreme temperatures – hot or cold – to destroy targeted areas in the heart associated with abnormal heart rhythms. FARAPULSE, however, relies on non-thermal electric fields to ablate heart tissue and avoid damage to surrounding structures.
“We are excited to be able to bring the very best in treatment options to our community, especially in areas that relate to prevalent, complex conditions of the heart,” said Derrick Glum, CEO of Saint Mary’s Health Network. “It has been well documented the success of our Saint Mary’s cardiology and structural heart teams, and paired with the exceptional care and skill of our community physicians, we know this program will be incredibly impactful to our patients.”
Atrial fibrillation occurs when the top two chambers of the heart, the atria, beat too fast and with an irregular rhythm (fibrillation). AF, the most common type of arrhythmia, can decrease the heart’s pumping efficiency, which can cause blood cells to pool and stick together, forming clots in the heart, and lead to stroke. To learn more about Saint Mary’s cardiology, or to schedule an appointment with one of our cardiologists, please visit saintmarysreno.com/cardiology.